Genesis HealthCare (GEN) Tops Q2 EPS by 1c, revenue in-line, provides guidance

Genesis HealthCare (NASDAQ: GEN) reported Q2 EPS of $0.47, $0.01 better than the analyst estimate of $0.46. Revenue for the quarter came in at $946 million versus the consensus estimate of $946 million.

Q2 FY24 Non-GAAP Guidance

Q2 FY24 Revenue expected to be in the range of $940 to $950 million
Q2 FY24 EPS expected to be in the range of $0.46 to $0.48

Fiscal Year 2024 Non-GAAP Annual Guidance

FY24 Revenue expected to be in the range of $3.8 to $3.85 billion
FY24 EPS expected to be in the range of $1.95 to $2.02

For earnings history and earnings-related data on Genesis HealthCare (GEN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Sharon AI surges premarket; New Oriental gains, Medline slips
• RH (RH) Tops Q1 EPS by 12c